Indazole compounds as 5-HT4 receptor agonists

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions co...

Full description

Saved in:
Bibliographic Details
Main Authors Jasti Venkateswarlu, Mohammed Abdul Rasheed, Gagginapally Shankar Reddy, Shinde Anil Karbhari, Nirogi Ramakrishna
Format Patent
LanguageChinese
English
Published 17.08.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists 本发明涉及式(I)的新吲唑化合物,包括其立体异构体及其可药用盐,其中R是烷基或环烷基;(式II)本发明还涉及制备这样的化合物的方法和包含这样的化合物的药物组合物。本发明的化合物可用于治疗与5-羟基-色胺4(5-HT)受体激动剂相关的多种疾病。
AbstractList The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists 本发明涉及式(I)的新吲唑化合物,包括其立体异构体及其可药用盐,其中R是烷基或环烷基;(式II)本发明还涉及制备这样的化合物的方法和包含这样的化合物的药物组合物。本发明的化合物可用于治疗与5-羟基-色胺4(5-HT)受体激动剂相关的多种疾病。
Author Nirogi Ramakrishna
Mohammed Abdul Rasheed
Gagginapally Shankar Reddy
Shinde Anil Karbhari
Jasti Venkateswarlu
Author_xml – fullname: Jasti Venkateswarlu
– fullname: Mohammed Abdul Rasheed
– fullname: Gagginapally Shankar Reddy
– fullname: Shinde Anil Karbhari
– fullname: Nirogi Ramakrishna
BookMark eNrjYmDJy89L5WTQ9cxLSazKz0lVSM7PLcgvzUspVkgsVjDV9QgxUShKTU4tKMkvUkhMz8_LLC4p5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hgamFubGlkYGjsbEqAEAdzUrWA
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate 作为5-HT4受体激动剂的吲唑化合物
ExternalDocumentID CN105873920A
GroupedDBID EVB
ID FETCH-epo_espacenet_CN105873920A3
IEDL.DBID EVB
IngestDate Fri Jul 19 14:47:30 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CN105873920A3
Notes Application Number: CN201480068132
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160817&DB=EPODOC&CC=CN&NR=105873920A
ParticipantIDs epo_espacenet_CN105873920A
PublicationCentury 2000
PublicationDate 20160817
PublicationDateYYYYMMDD 2016-08-17
PublicationDate_xml – month: 08
  year: 2016
  text: 20160817
  day: 17
PublicationDecade 2010
PublicationYear 2016
RelatedCompanies Suven Life Sciences Ltd
RelatedCompanies_xml – name: Suven Life Sciences Ltd
Score 3.1644037
Snippet The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Indazole compounds as 5-HT4 receptor agonists
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160817&DB=EPODOC&locale=&CC=CN&NR=105873920A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwED7mFPVNp6LzBxGkb8WVNkv7UMSlLVVYN6TK3kbTplMRW2xF2F_vpXTOF30LCSS5gy933-VyAbgyqZOjV2vrTGQUCUpKdTGkiU6FQVPDYPlAqnjHOBqGj9b9jM468Lp6C9PUCf1qiiMiolLEe92c1-U6iOU1uZXVtXjBruImiF1Pa9mxMUQLxzRv5PrTiTfhGucuj7ToAX1dajP0BQa3G7CJbjRTaPCfRupVSvnbpAR7sDXF2d7rfegsn3uww1c_r_Vge9xeeGOzxV51APodsudl8SaJSgNXvyFVJKkI1cPYInhuyRLpM0kWhaqFWx3CZeDHPNRx3fmPkHMerbdoHkEXyb88BpKadpbKzLRywSxkc45pUUcIFEDYeWanJ9D_e57-f4OnsKsUpuKjBjuDbv3xKc_RwNbiotHMN-MkfmQ
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFOebTmXOrwrSt-JKm6V9KOLSjU7XbkiVvY0lTf1AbLEVYX-9l7I5X_QtJHBJDu7jd8ndAVxaxE3Rq3UMyhOCAEUQg3fJ3CDcJMI0adqRKt4RRt3gwb6dkmkNXle5MFWd0K-qOCJKlEB5Lyt9na-DWH71t7K44i84lV0PYs_Xl-jY7KKFo7rf8_qTsT9mOmMei_ToHn1d4lD0BTo3G7CJLjZV0tB_7KmslPy3SRnswtYEqb2Xe1BbPDehwVad15qwHS4fvHG4lL1iH4whoudF9iY19Q1cdUMqtHmhESOIbQ31lswRPmvzp0zVwi0O4GLQj1lg4L6zn0vOWLQ-onUIdQT_sgWasJxEyMSyU05tRHOuZROXc0Iod9LEEUfQ_ptO-7_Fc2gEcTiajYbR3THsKOapWKlJT6BefnzKUzS2JT-ruPQN-zqBVw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Indazole+compounds+as+5-HT4+receptor+agonists&rft.inventor=Jasti+Venkateswarlu&rft.inventor=Mohammed+Abdul+Rasheed&rft.inventor=Gagginapally+Shankar+Reddy&rft.inventor=Shinde+Anil+Karbhari&rft.inventor=Nirogi+Ramakrishna&rft.date=2016-08-17&rft.externalDBID=A&rft.externalDocID=CN105873920A